---
title: "《回顾》国指 2025 年上半年五大最强及最弱股份 (表)"
description: "国指 2025 年上半年表现总结：五大最强股份为小米-W(+73.8%)、石药 (+61.1%)、快手-W(+53.1%)、京东健康 (+53.0%)、网易-S(+52.5%)；五大最弱股份为海尔智家 (-18.4%)、美团-W(-17.4%)、携程-S(-15.6%)、新东方-S(-13.9%)、申洲国际 (-10.0%)。国指累计升幅为 1,388 点，涨幅 19.0%，收于 8,678 点。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/246635110.md"
published_at: "2025-06-30T09:23:31.000Z"
---

# 《回顾》国指 2025 年上半年五大最强及最弱股份 (表)

> 国指 2025 年上半年表现总结：五大最强股份为小米-W(+73.8%)、石药 (+61.1%)、快手-W(+53.1%)、京东健康 (+53.0%)、网易-S(+52.5%)；五大最弱股份为海尔智家 (-18.4%)、美团-W(-17.4%)、携程-S(-15.6%)、新东方-S(-13.9%)、申洲国际 (-10.0%)。国指累计升幅为 1,388 点，涨幅 19.0%，收于 8,678 点。

国指 2025 年上半年五大最强股份：

股份│上半年股价变幅

小米-W(01810.HK)│+73.8%

石药 (01093.HK)│+61.1%

快手-W(01024.HK)│+53.1%

京东健康 (06618.HK)│+53.0%

网易-S(09999.HK)│+52.5%

国指 2025 年上半年五大最弱股份：

股份│上半年股价变幅

海尔智家 (06690.HK)│-18.4%

美团-W(03690.HK)│-17.4%

携程-S(09961.HK)│-15.6%

新东方-S(09901.HK)│-13.9%

申洲国际 (02313.HK)│-10.0%

总结国指 2025 上半年累升 1,388 点或 19.0%，收 8,678 点。

### Related Stocks

- [06618.HK - 京东健康](https://longbridge.com/zh-CN/quote/06618.HK.md)
- [01093.HK - 石药集团](https://longbridge.com/zh-CN/quote/01093.HK.md)
- [09901.HK - 新东方-S](https://longbridge.com/zh-CN/quote/09901.HK.md)
- [02313.HK - 申洲国际](https://longbridge.com/zh-CN/quote/02313.HK.md)
- [01024.HK - 快手-W](https://longbridge.com/zh-CN/quote/01024.HK.md)
- [09999.HK - 网易-S](https://longbridge.com/zh-CN/quote/09999.HK.md)
- [06690.HK - 海尔智家](https://longbridge.com/zh-CN/quote/06690.HK.md)
- [03690.HK - 美团-W](https://longbridge.com/zh-CN/quote/03690.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |
| China tightens oversight of online ticket platforms, targets paid priority purchase claims | The Beijing Municipal Administration for Market Regulation has conducted interviews with 12 major online ticket platform | [Link](https://longbridge.com/zh-CN/news/275689507.md) |
| CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF) | CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally,  | [Link](https://longbridge.com/zh-CN/news/274393834.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。